Enterprise Value

22.77M

Cash

201M

Avg Qtr Burn

-5.28M

Short % of Float

4.77%

Insider Ownership

35.14%

Institutional Own.

13.52%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Natrunix Details
Rheumatoid arthritis, Autoimmune disease

Phase 2

Data readout

Phase 1/2

Update

Hutrukin Details
Brain disease, Ischemic stroke

Phase 1

Data readout

Phase 1

Update

Bermekimab Details
Skin disease/disorder, Hidradenitis suppurativa

Failed

Discontinued

Bermekimab Details
Skin disease/disorder

Failed

Discontinued

514G3 Details
Bacterial infection, Methicillin-resistant staphylococcus aureus

Failed

Discontinued